(Q33845393)

29 July 2017

title

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials (English)

1 reference

29 July 2017

main subject

phase II clinical trial

0 references

0 references

1 reference

J D Wolchok

1

1 reference

29 July 2017

J S Weber

2

1 reference

29 July 2017

M Maio

3

1 reference

29 July 2017

B Neyns

4

1 reference

29 July 2017

K Harmankaya

5

1 reference

29 July 2017

K Chin

6

1 reference

29 July 2017

L Cykowski

7

1 reference

29 July 2017

V de Pril

8

1 reference

29 July 2017

R Humphrey

9

1 reference

29 July 2017

C Lebbé

10

1 reference

29 July 2017

language of work or name

1 reference

10 May 2013

1 reference

29 July 2017

1 reference

29 July 2017

volume

24

1 reference

29 July 2017

issue

8

1 reference

29 July 2017

page(s)

2174-2180

1 reference

Upcoming strategies for the treatment of metastatic melanoma.

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Systematic review of medical treatment in melanoma: current status and future prospects.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Improved endpoints for cancer immunotherapy trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Final version of 2009 AJCC melanoma staging and classification

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081656

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT161

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT161

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT161

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT161

1 reference

29 July 2017

1 reference

29 July 2017

1 reference